Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage

Andrologia
H ZhuQ-Z Liu

Abstract

Thirteen strains of Chlamydia trachomatis were exposed to subinhibitory concentrations of erythromycin (0.5 microg ml(-1)), azithromycin (0.5 microg ml(-1)) and josamycin (0.04 microg ml(-1)) to select macrolide-resistant mutants with serial passages. The C. trachomatis mutants presented with low-level resistance to erythromycin, azithromycin and josamycin for which a 16-fold increase, a 16-fold increase and an 8-fold increase respectively in the minimal inhibitory concentration (MICs) for the mutant strains compared with the MIC for the susceptible strains were found. The results of chemosensitivity showed that josamycin had the highest susceptibility rate compared with erythromycin and azithromycin in the treatment of C. trachomatis. The ribosomal protein L4 and 23S rRNA genes of the susceptible and resistant strains of C. trachomatis were partially sequenced. A double mutation was found in ribosomal protein L4 of the mutants, leading to Pro109(CCG)-->Leu(CTG), and Pro151(CCG)-->Ala(GCC) (Escherichia coli numbering) in the corresponding protein, but these mutations were also found in parent strains. An investigation into the sequences of 23S rRNAs in the mutants revealed point mutations of A2057G, A2059G and T2611C (E. coli n...Continue Reading

References

Nov 1, 1980·Antimicrobial Agents and Chemotherapy·A MouradJ Schachter
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·B Weisblum
Nov 14, 1998·Journal of Molecular Biology·P OstergaardR A Garrett
Dec 3, 1999·Antimicrobial Agents and Chemotherapy·M C RobertsH Seppala
Apr 14, 2000·The Journal of Infectious Diseases·J SomaniC M Black
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·B Vester, S Douthwaite
Jul 14, 2001·Antimicrobial Agents and Chemotherapy·J LenartD D Rockey
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Marja PihlajamäkiJari Jalava
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·R J SuchlandWalter E Stamm
Jul 3, 2003·Journal of Bacteriology·Rita BerisioAda Yonath
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·O Y MisyurinaV M Govorun
May 28, 2004·The Journal of Antimicrobial Chemotherapy·Priscilla B Wyrick, Stephen T Knight
Jul 9, 2004·Critical Reviews in Microbiology·Daniele Corsaro, Danielle Venditti
Feb 18, 2005·The Journal of Infectious Diseases·Susan A WangKing K Holmes
Feb 25, 2005·Antimicrobial Agents and Chemotherapy·Andrei KutlinPaul Riska
Mar 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Peter PfisterErik C Böttger

❮ Previous
Next ❯

Citations

Jul 23, 2013·International Journal of Antimicrobial Agents·Cláudia GomesJoaquim Ruiz
Nov 28, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Cláudia GomesJoaquim Ruiz
Aug 21, 2013·BMC Infectious Diseases·Jane S HockingUNKNOWN Australian Chlamydia Treatment Study (ACTS) investigators
Mar 8, 2013·Future Microbiology·Jane S HockingSepehr N Tabrizi
Nov 13, 2014·BMC Infectious Diseases·Mette T ChristiansenJudith Breuer
Jul 30, 2015·BMC Infectious Diseases·Fabian Yuh Shiong Kong, Jane Simone Hocking
Sep 5, 2021·Annals of Clinical Microbiology and Antimicrobials·Ichrak BenamriFouzia Radouani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.